Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Revenue - Other
Ratios

Perspective Therapeutics (CATX) Cost of Revenue (2016 - 2023)

Historic Cost of Revenue for Perspective Therapeutics (CATX) over the last 14 years, with Q4 2023 value amounting to -$4.9 million.

  • Perspective Therapeutics' Cost of Revenue changed N/A to -$4.9 million in Q4 2023 from the same period last year, while for Sep 2023 it was $6.2 million, marking a year-over-year increase of 368.25%. This contributed to the annual value of $6.2 million for FY2022, which is 2528.39% up from last year.
  • Perspective Therapeutics' Cost of Revenue amounted to -$4.9 million in Q4 2023.
  • Perspective Therapeutics' Cost of Revenue's 5-year high stood at $1.8 million during Q2 2023, with a 5-year trough of -$4.9 million in Q4 2023.
  • Moreover, its 5-year median value for Cost of Revenue was $1.2 million (2021), whereas its average is $1.0 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 3488.58% in 2021, then tumbled by 1511.4% in 2022.
  • Over the past 5 years, Perspective Therapeutics' Cost of Revenue (Quarter) stood at $1.1 million in 2019, then grew by 8.86% to $1.2 million in 2020, then soared by 33.89% to $1.6 million in 2021, then fell by 18.36% to $1.3 million in 2022, then tumbled by 473.22% to -$4.9 million in 2023.
  • Its Cost of Revenue stands at -$4.9 million for Q4 2023, versus $1.4 million for Q3 2023 and $1.8 million for Q2 2023.